RegentAtlantic Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $11.6M | Sell |
86,356
-1,985
| -2% | -$285K | 0.35% | 45 |
|
|
2022
Q2 | $13.5M | Buy |
88,341
+4,596
| +5% | +$702K | 0.45% | 35 |
|
|
2022
Q1 | $13.6M | Buy |
83,745
+2,992
| +4% | +$435K | 0.38% | 45 |
|
|
2021
Q4 | $10.9M | Buy |
80,753
+1,183
| +1% | +$140K | 0.31% | 56 |
|
|
2021
Q3 | $8.58M | Buy |
79,570
+5,937
| +8% | +$678K | 0.26% | 68 |
|
|
2021
Q2 | $8.29M | Buy |
73,633
+7,924
| +12% | +$892K | 0.25% | 70 |
|
|
2021
Q1 | $7.11M | Buy |
65,709
+7,460
| +13% | +$798K | 0.24% | 79 |
|
|
2020
Q4 | $6.24M | Buy |
58,249
+7,271
| +14% | +$699K | 0.25% | 81 |
|
|
2020
Q3 | $4.46M | Buy |
50,978
+20,451
| +67% | +$1.93M | 0.2% | 96 |
|
|
2020
Q2 | $3M | Buy |
30,527
+10,203
| +50% | +$898K | 0.17% | 116 |
|
|
2020
Q1 | $1.55M | Sell |
20,324
-35,167
| -63% | -$3M | 0.12% | 161 |
|
|
2019
Q4 | $4.91M | Sell |
55,491
-101
| -0.2% | -$8.38K | 0.3% | 90 |
|
|
2019
Q3 | $4.21M | Buy |
55,592
+262
| +0.5% | +$18K | 0.28% | 95 |
|
|
2019
Q2 | $4.02M | Sell |
55,330
-161
| -0.3% | -$12.7K | 0.27% | 91 |
|
|
2019
Q1 | $4.47M | Buy |
55,491
+4,405
| +9% | +$360K | 0.31% | 85 |
|
|
2018
Q4 | $4.71M | Buy |
51,086
+36,080
| +240% | +$3.17M | 0.4% | 77 |
|
|
2018
Q3 | $1.42M | Buy |
15,006
+1,016
| +7% | +$96.3K | 0.11% | 189 |
|
|
2018
Q2 | $1.3M | Sell |
13,990
-50
| -0.4% | -$4.88K | 0.11% | 184 |
|
|
2018
Q1 | $1.33M | Sell |
14,040
-896
| -6% | -$98.4K | 0.11% | 192 |
|
|
2017
Q4 | $1.44M | Sell |
14,936
-1,425
| -9% | -$134K | 0.12% | 185 |
|
|
2017
Q3 | $1.45M | Buy |
16,361
+74
| +0.5% | +$5.63K | 0.13% | 175 |
|
|
2017
Q2 | $1.18M | Sell |
16,287
-84
| -0.5% | -$5.65K | 0.11% | 194 |
|
|
2017
Q1 | $1.07M | Buy |
16,371
+834
| +5% | +$52.4K | 0.1% | 198 |
|
|
2016
Q4 | $973K | Buy |
15,537
+18
| +0.1% | +$1.1K | 0.09% | 205 |
|
|
2016
Q3 | $979K | Buy |
15,519
+1,179
| +8% | +$76.3K | 0.1% | 197 |
|
|
2016
Q2 | $888K | Sell |
14,340
-875
| -6% | -$53.3K | 0.09% | 197 |
|
|
2016
Q1 | $869K | Buy |
15,215
+30
| +0.2% | +$1.67K | 0.1% | 178 |
|
|
2015
Q4 | $900K | Sell |
15,185
-2,166
| -12% | -$125K | 0.1% | 194 |
|
|
2015
Q3 | $944K | Sell |
17,351
-3,278
| -16% | -$213K | 0.09% | 185 |
|
|
2015
Q2 | $1.39M | Buy |
20,629
+565
| +3% | +$36.9K | 0.12% | 158 |
|
|
2015
Q1 | $1.18M | Sell |
20,064
-310
| -2% | -$18.7K | 0.1% | 173 |
|
|
2014
Q4 | $1.33M | Buy |
20,374
+19
| +0.1% | +$1.2K | 0.11% | 163 |
|
|
2014
Q3 | $1.18M | Sell |
20,355
-1,464
| -7% | -$81.3K | 0.11% | 164 |
|
|
2014
Q2 | $1.23M | Sell |
21,819
-229
| -1% | -$12K | 0.11% | 159 |
|
|
2014
Q1 | $1.13M | Sell |
22,048
-1,754
| -7% | -$88.6K | 0.11% | 163 |
|
|
2013
Q4 | $1.26M | Sell |
23,802
-283
| -1% | -$13.9K | 0.12% | 152 |
|
|
2013
Q3 | $1.08M | Buy |
24,085
+6,497
| +37% | +$288K | 0.12% | 156 |
|
|
2013
Q2 | $727K | Buy |
+17,588
| New | +$769K | 0.09% | 186 |
|
Other funds holding ABBV
RegentAtlantic Capital's ABBV Position: Q3 2022 in Review
RegentAtlantic Capital reduced its AbbVie (ABBV) stake by 2.2% in Q3 2022, selling an estimated $285K and leaving 86,356 shares worth $11.6M. The position accounts for 0.35% of the portfolio, ranked #45.
RegentAtlantic Capital first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $13.6M in Q1 2022. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.
- RegentAtlantic Capital held 86,356 shares of AbbVie worth $11.6M as of Q3 2022.
- RegentAtlantic Capital sold 1,985 AbbVie shares in Q3 2022, an estimated $285K.
- AbbVie made up 0.35% of RegentAtlantic Capital's portfolio in Q3 2022, its #45 holding.
- RegentAtlantic Capital first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- RegentAtlantic Capital's AbbVie position peaked at $13.6M in Q1 2022.
- 2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.